These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 10675987)

  • 21. Tipranavir: PNU 140690, tipranivir.
    Drugs R D; 2006; 7(1):55-62. PubMed ID: 16620137
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
    Ghosh AK; Chapsal BD; Weber IT; Mitsuya H
    Acc Chem Res; 2008 Jan; 41(1):78-86. PubMed ID: 17722874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19.
    Hirani VN; Raucy JL; Lasker JM
    Drug Metab Dispos; 2004 Dec; 32(12):1462-7. PubMed ID: 15448116
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modular construction of quaternary hemiaminal-based inhibitor candidates and their in cellulo assessment with HIV-1 protease.
    Gros G; Martinez L; Gimenez AS; Adler P; Maurin P; Wolkowicz R; Falson P; Hasserodt J
    Bioorg Med Chem; 2013 Sep; 21(17):5407-13. PubMed ID: 23911197
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dimeric 4-aryl-1,4-dihydropyridines as novel HIV-1 protease inhibitors--affinities to intestinal P-glycoprotein.
    Hilgeroth A; Dressler C; Neuhoff S; Spahn-Langguth H; Langguth P
    Pharmazie; 2000 Oct; 55(10):784-5. PubMed ID: 11082847
    [No Abstract]   [Full Text] [Related]  

  • 26. Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavir.
    Kevin NJ; Duffy JL; Kirk BA; Chapman KT; Schleif WA; Olsen DB; Stahlhut M; Rutkowski CA; Kuo LC; Jin L; Lin JH; Emini EA; Tata JR
    Bioorg Med Chem Lett; 2003 Nov; 13(22):4027-30. PubMed ID: 14592500
    [TBL] [Abstract][Full Text] [Related]  

  • 27. L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor.
    Dorsey BD; Levin RB; McDaniel SL; Vacca JP; Guare JP; Darke PL; Zugay JA; Emini EA; Schleif WA; Quintero JC
    J Med Chem; 1994 Oct; 37(21):3443-51. PubMed ID: 7932573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Modified P1 Moiety Enhances In Vitro Antiviral Activity against Various Multidrug-Resistant HIV-1 Variants and In Vitro Central Nervous System Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413.
    Amano M; Salcedo-Gómez PM; Zhao R; Yedidi RS; Das D; Bulut H; Delino NS; Sheri VR; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7046-7059. PubMed ID: 27620483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells.
    Zhong DS; Lu XH; Conklin BS; Lin PH; Lumsden AB; Yao Q; Chen C
    Arterioscler Thromb Vasc Biol; 2002 Oct; 22(10):1560-6. PubMed ID: 12377730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure-based design of nonpeptidic HIV protease inhibitors from a cyclooctylpyranone lead structure.
    Romines KR; Watenpaugh KD; Howe WJ; Tomich PK; Lovasz KD; Morris JK; Janakiraman MN; Lynn JC; Horng MM; Chong KT
    J Med Chem; 1995 Oct; 38(22):4463-73. PubMed ID: 7473573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel nonpeptidic inhibitors of HIV-1 protease obtained via a new multicomponent chemistry strategy.
    Yehia NA; Antuch W; Beck B; Hess S; Schauer-Vukasinović V; Almstetter M; Furer P; Herdtweck E; Dömling A
    Bioorg Med Chem Lett; 2004 Jun; 14(12):3121-5. PubMed ID: 15149657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis, 2D-NMR and molecular modelling studies of pentacycloundecane lactam-peptides and peptoids as potential HIV-1 wild type C-SA protease inhibitors.
    Makatini MM; Petzold K; Alves CN; Arvidsson PI; Honarparvar B; Govender P; Govender T; Kruger HG; Sayed Y; JerônimoLameira ; Maguire GE; Soliman ME
    J Enzyme Inhib Med Chem; 2013 Feb; 28(1):78-88. PubMed ID: 22339087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis and QSAR studies on N-aryl heteroarylisopropanolamines, a new class of non-peptidic HIV-1 protease inhibitors.
    Di Santo R; Costi R; Artico M; Massa S; Ragno R; Marshall GR; La Colla P
    Bioorg Med Chem; 2002 Aug; 10(8):2511-26. PubMed ID: 12057640
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma protein binding properties of dimeric 4-aryl-1,4-dihydropyridines as novel non peptidic HIV-1 protease inhibitors.
    Hilgeroth A; Langner A
    Pharmazie; 2000 Jul; 55(7):542-3. PubMed ID: 10944788
    [No Abstract]   [Full Text] [Related]  

  • 35. Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class.
    Turner SR; Strohbach JW; Tommasi RA; Aristoff PA; Johnson PD; Skulnick HI; Dolak LA; Seest EP; Tomich PK; Bohanon MJ; Horng MM; Lynn JC; Chong KT; Hinshaw RR; Watenpaugh KD; Janakiraman MN; Thaisrivongs S
    J Med Chem; 1998 Aug; 41(18):3467-76. PubMed ID: 9719600
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combinatorial diversification of indinavir: in vivo mixture dosing of an HIV protease inhibitor library.
    Rano TA; Cheng Y; Huening TT; Zhang F; Schleif WA; Gabryelski L; Olsen DB; Kuo LC; Lin JH; Xu X; Olah TV; McLoughlin DA; King R; Chapman KT; Tata JR
    Bioorg Med Chem Lett; 2000 Jul; 10(14):1527-30. PubMed ID: 10915042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biological evaluation of bishydroxymethyl-substituted cage dimeric 1,4-dihydropyridines as a novel class of p-glycoprotein modulating agents in cancer cells.
    Richter M; Molnár J; Hilgeroth A
    J Med Chem; 2006 May; 49(9):2838-40. PubMed ID: 16640345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tipranavir: a ritonavir-boosted protease inhibitor.
    Croom KF; Keam SJ
    Drugs; 2005; 65(12):1669-77; discussion 1678-9. PubMed ID: 16060700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A symmetric inhibitor binds HIV-1 protease asymmetrically.
    Dreyer GB; Boehm JC; Chenera B; DesJarlais RL; Hassell AM; Meek TD; Tomaszek TA; Lewis M
    Biochemistry; 1993 Jan; 32(3):937-47. PubMed ID: 8422397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters.
    Hagen SE; Domagala J; Gajda C; Lovdahl M; Tait BD; Wise E; Holler T; Hupe D; Nouhan C; Urumov A; Zeikus G; Zeikus E; Lunney EA; Pavlovsky A; Gracheck SJ; Saunders J; VanderRoest S; Brodfuehrer J
    J Med Chem; 2001 Jul; 44(14):2319-32. PubMed ID: 11428926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.